Development of treatment and clinical results in childhood acute myeloid leukemia in Poland

[1]  D. Campana,et al.  Treatment outcome in older patients with childhood acute myeloid leukemia , 2012, Cancer.

[2]  M. Abrar,et al.  Improved outcome in pediatric AML due to augmented supportive care , 2012, Pediatric blood & cancer.

[3]  W. Wood,et al.  Outcomes of allogeneic hematopoietic cell transplantation for adolescent and young adults compared with children and older adults with acute myeloid leukemia. , 2012, Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation.

[4]  D. Reinhardt,et al.  The role of matched sibling donor allogeneic stem cell transplantation in pediatric high-risk acute myeloid leukemia: results from the AML-BFM 98 study , 2012, Haematologica.

[5]  M. Jarfelt,et al.  Quality of health in survivors of childhood acute myeloid leukemia treated with chemotherapy only: A NOPHO‐AML study , 2011, Pediatric blood & cancer.

[6]  A. Teigler‐Schlegel,et al.  Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16). , 2011, Blood.

[7]  K. Wheatley,et al.  Results of a randomized trial in children with Acute Myeloid Leukaemia: Medical Research Council AML12 trial , 2011, British journal of haematology.

[8]  T. Alonzo,et al.  Soluble interleukin‐2 receptor α activation in a Children's Oncology Group randomized trial of interleukin‐2 Therapy for Pediatric Acute Myeloid Leukemia , 2011, Pediatric blood & cancer.

[9]  S. Raimondi,et al.  Prognostic significance of additional cytogenetic aberrations in 733 de novo pediatric 11q23/MLL-rearranged AML patients: results of an international study. , 2011, Blood.

[10]  K. Jahnukainen,et al.  Response-guided induction therapy in pediatric acute myeloid leukemia with excellent remission rate. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  U. Creutzig,et al.  A review on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia. , 2010, Blood.

[12]  M. Loh,et al.  Outcome for children treated for relapsed or refractory acute myelogenous leukemia (rAML): A therapeutic advances in childhood leukemia (TACL) consortium study , 2010, Pediatric blood & cancer.

[13]  J. Neglia,et al.  Health and risk behaviors in survivors of childhood acute myeloid leukemia: A report from the Children's Oncology Group , 2010, Pediatric blood & cancer.

[14]  D. Reinhardt,et al.  Consequent and intensified relapse therapy improved survival in pediatric AML: results of relapse treatment in 379 patients of three consecutive AML-BFM trials , 2010, Leukemia.

[15]  Elaine Coustan-Smith,et al.  Minimal residual disease-directed therapy for childhood acute myeloid leukaemia: results of the AML02 multicentre trial. , 2010, The Lancet. Oncology.

[16]  G. Lyman,et al.  Impact of disease risk on efficacy of matched related bone marrow transplantation for pediatric acute myeloid leukemia: the Children's Oncology Group. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  D. Reinhardt,et al.  Place of HSCT in treatment of childhood AML , 2008, Bone Marrow Transplantation.

[18]  R. Schlenk,et al.  Significance of age in acute myeloid leukemia patients younger than 30 years , 2008, Cancer.

[19]  C. Zwaan,et al.  Pediatric acute myeloid leukemia: towards high-quality cure of all patients , 2007, Haematologica.

[20]  J. Wachowiak,et al.  Twenty years of Polish experience with three consecutive protocols for treatment of childhood acute myelogenous leukemia , 2005, Leukemia.

[21]  D. Reinhardt,et al.  Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J. Nunemacher,et al.  Optimal management of giant cell arteritis and polymyalgia rheumatica , 2012, Therapeutics and clinical risk management.

[23]  C. Niemeyer,et al.  Idarubicin improves blast cell clearance during induction therapy in children with AML: results of study AML-BFM 93 , 2001, Leukemia.

[24]  J. Reiffers,et al.  A prospective randomized trial of idarubicin vs daunorubicin in combination chemotherapy for acute myelogenous leukemia of the age group 55 to 75. , 1996, Leukemia.

[25]  C. Arndt,et al.  New Agents for Treatment of Children With Acute Myelogenous Leukemia , 1995, Journal of pediatric hematology/oncology.

[26]  J. Ritter,et al.  Identification of two risk groups in childhood acute myelogenous leukemia after therapy intensification in study AML-BFM-83 as compared with study AML-BFM-78. AML-BFM Study Group. , 1990, Blood.

[27]  D. Sońta‐Jakimczyk,et al.  [Preliminary evaluation of the results of treatment of myeloblastic leukemia using the AML-BFM-83 protocol based on data from the Polish Group for the Treatment of Leukemia in Children]. , 1988, Polski tygodnik lekarski.

[28]  W. Młynarski,et al.  [Genotyping and minimal residual disease study in children with acute myeloid leukemia: preliminary results]. , 2010, Przeglad lekarski.

[29]  J. Wachowiak,et al.  [Treatment failure in children with acute myelocytic leukemia: over 25-year experience of Polish Pediatric Leukemia/Lymphoma Study Group with four consecutive unified treatment protocols for childhood acute myelocytic leukemia]. , 2010, Przeglad lekarski.

[30]  R. Rokicka‐Milewska,et al.  [Intermediate doses of cytosine arabinoside in the treatment of acute non-lymphoblastic leukaemia in children]. , 2000, Medycyna wieku rozwojowego.